Ian Estepan | VP, Chief, Staff and Corporate Affairs |
Doug Ingram | CEO |
Sandy Mahatme | CFO |
Bo Cumbo | Chief Commercial Officer |
Dr. Gilmore O’Neill | Chief Medical Officer |
Dr. Louise Rodino-Klapac | VP, Gene Therapy |
Ritu Baral | Cowen |
Brian Abrahams | RBC Capital Markets |
Christopher Marai | Nomura Instinet |
Brian Skorney | Baird |
Matthew Harrison | Morgan Stanley |
Ross Weinreb | Goldman Sachs |
Dae Gon Ha | Leerink Partners |
Debjit Chattopadhyay | H. C. Wainwright |
Jon Wolleben | JMP Securities |
Myles Minter | William Blair |
Hartaj Singh | Oppenheimer |
Yun Zhong | Janney |
Tim Chiang | BTIG |
Gena Wang | Barclays |
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Ian Estepan, Vice President, Chief of Staff and Corporate Affairs.